CRH to buy Arcosa in $8.5 billion deal
CRH (NYSE:CRH) signed a definitive agreement to purchase competitor Arcosa for $150 per share in cash.
CRH (NYSE:CRH) signed a definitive agreement to purchase competitor Arcosa for $150 per share in cash.
Fervo Energy (NASDAQ:FRVO) reported a first-quarter net loss of $31.8 million while funding multiple utility-scale geothermal facilities.
Galmed Pharmaceuticals (NASDAQ:GLMD) closed its Colospan acquisition, gaining a device tested on 97 patients.
Definium Therapeutics (NASDAQ:DFTX) stated its depression drug trial succeeded, showing a key 8.1-point improvement over a placebo.
AbbVie (NYSE:ABBV) executed an agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for $135.11 per share in cash, totaling approximately $10.9 billion.
HawkEye 360 (NYSE:HAWK) achieved record first-quarter 2026 revenue of $49.8 million due to strong global demand.
Merck (NYSE:MRK) announced positive topline results from its Phase 3 study evaluating tulisokibart for active ulcerative colitis.
Ennis (NYSE:EBF) reported a 1.4% increase in first-quarter revenue to $98.6 million for the period ended May 31, 2026.
Petróleo Brasileiro, also known as Petrobas (NYSE:PBR) approved the final investment decision for a $1.2 billion biorefining project to produce renewable fuels.
Baker Hughes (NASDAQ:BKR) is discussing potential commitments with the European Commission to clear its acquisition of Chart Industries (NYSE:GTLS).
MOGU (NYSE:MOGU) posted an 11.2% decline in fiscal year 2026 total revenues to RMB125.4 million due to heightened competition.
ECARX (NASDAQ:ECX) signed a definitive agreement to acquire the Flyme software business for RMB1.8 billion ($266 million)